Trial Profile
An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2019
Price :
$35
*
At a glance
- Drugs Tapentadol (Primary)
- Indications Back pain
- Focus Registrational; Therapeutic Use
- Sponsors Grunenthal
- 23 Mar 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 01 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2010 Planned end date changed from 1 Jun 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.